Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

The radiopharmaceutical sector is in the midst of a transformative year in 2026, with significant developments and challenges, including policy and reimbursement, increasing demand and growth within precision oncology and molecular imaging, and the need for specialised CDMOs when it comes to the intricate nature of radiopharmaceutical manufacturing. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Andrew Cavey, CEO of ITM, about current and future radiopharmaceutical trends. Dr Cavey discusses the evolution of radiopharma, beyond the original “two pillars” of GEP-NETs and PSMA, including the move towards a multi-isotope model, as well as ITM’s pipeline and the potential growth of the broader radiopharma ecosystem going forward. You can listen to episode 263 of the pharmaphorum podcast (https://pharmaphorum.com/podcasts)  in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts (https://podcasts.apple.com/gb/podcast...) , Spotify (https://open.spotify.com/show/1wbZ50I...) , Overcast, Pocket Casts, Podbean (https://pharmaphorum.podbean.com/) , and pretty much wherever else you download your other podcasts from.